Cargando…

Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy

Background and Objective: This study evaluated the relationship between microsatellite status (MSI) and pan-immune-inflammation score (PIV) in tumor response to neoadjuvant chemotherapy (NAC) in patients with clinical stage III gastric cancer (cStage III GC). Materials and Methods: Microsatellite in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulmez, Ahmet, Coskun, Hatice, Koseci, Tolga, Ata, Serdar, Bozkurt, Berna, Cil, Timucin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537642/
https://www.ncbi.nlm.nih.gov/pubmed/37763744
http://dx.doi.org/10.3390/medicina59091625
_version_ 1785113148677685248
author Gulmez, Ahmet
Coskun, Hatice
Koseci, Tolga
Ata, Serdar
Bozkurt, Berna
Cil, Timucin
author_facet Gulmez, Ahmet
Coskun, Hatice
Koseci, Tolga
Ata, Serdar
Bozkurt, Berna
Cil, Timucin
author_sort Gulmez, Ahmet
collection PubMed
description Background and Objective: This study evaluated the relationship between microsatellite status (MSI) and pan-immune-inflammation score (PIV) in tumor response to neoadjuvant chemotherapy (NAC) in patients with clinical stage III gastric cancer (cStage III GC). Materials and Methods: Microsatellite instability (MSI) status was evaluated based on pathology preparations. Pan-immune-inflammation score (PIV) was obtained from pre-treatment blood tests. The relationship of both parameters with pathological complete response (pCR) was evaluated. Results: A total of 104 patients were included in this study. All the patients were stage III GC patients receiving perioperative treatment. There were 13 patients in total who achieved a pCR response. While CNS was detected in 11 of the patients who achieved a pCR, the MSI status of the other two patients was unknown. No pCR was observed in any patient with MSI-H. According to the cut-off value for PIV, 25 (24%) patients were in the PIV-low (≤53.9) group, while 79 (76%) were in the PIV-high (>53.9) group. Based on univariate analysis, a higher PIV was associated with worse outcomes for pathological response, disease recurrence, and survival (p < 0.05). Conclusions: In patients with clinically stage III GC, the presence of MSI-H may predict no benefit from perioperative treatment. Conversely, a pre-treatment PIV score using specific cut-off values may provide a positive prediction of pathological response and survival.
format Online
Article
Text
id pubmed-10537642
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105376422023-09-29 Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy Gulmez, Ahmet Coskun, Hatice Koseci, Tolga Ata, Serdar Bozkurt, Berna Cil, Timucin Medicina (Kaunas) Article Background and Objective: This study evaluated the relationship between microsatellite status (MSI) and pan-immune-inflammation score (PIV) in tumor response to neoadjuvant chemotherapy (NAC) in patients with clinical stage III gastric cancer (cStage III GC). Materials and Methods: Microsatellite instability (MSI) status was evaluated based on pathology preparations. Pan-immune-inflammation score (PIV) was obtained from pre-treatment blood tests. The relationship of both parameters with pathological complete response (pCR) was evaluated. Results: A total of 104 patients were included in this study. All the patients were stage III GC patients receiving perioperative treatment. There were 13 patients in total who achieved a pCR response. While CNS was detected in 11 of the patients who achieved a pCR, the MSI status of the other two patients was unknown. No pCR was observed in any patient with MSI-H. According to the cut-off value for PIV, 25 (24%) patients were in the PIV-low (≤53.9) group, while 79 (76%) were in the PIV-high (>53.9) group. Based on univariate analysis, a higher PIV was associated with worse outcomes for pathological response, disease recurrence, and survival (p < 0.05). Conclusions: In patients with clinically stage III GC, the presence of MSI-H may predict no benefit from perioperative treatment. Conversely, a pre-treatment PIV score using specific cut-off values may provide a positive prediction of pathological response and survival. MDPI 2023-09-08 /pmc/articles/PMC10537642/ /pubmed/37763744 http://dx.doi.org/10.3390/medicina59091625 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gulmez, Ahmet
Coskun, Hatice
Koseci, Tolga
Ata, Serdar
Bozkurt, Berna
Cil, Timucin
Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy
title Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy
title_full Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy
title_fullStr Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy
title_full_unstemmed Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy
title_short Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy
title_sort effect of microsatellite status and pan-immune-inflammation score on pathological response in patients with clinical stage iii stomach cancer treated with perioperative chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537642/
https://www.ncbi.nlm.nih.gov/pubmed/37763744
http://dx.doi.org/10.3390/medicina59091625
work_keys_str_mv AT gulmezahmet effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy
AT coskunhatice effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy
AT kosecitolga effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy
AT ataserdar effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy
AT bozkurtberna effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy
AT ciltimucin effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy